Amarin boosted as another milestone to the FDA’s big Vascepa decision flies by with no sign of an AdCom

Amarin stock got a boost Wednesday morning as the company posted a nice spike in Vascepa sales for the latest quarter and company execs declared themselves satisfied now that an AdCom on Vascepa is “unlikely” ahead of a late September PDUFA date.